Press "Enter" to skip to content

Combination Anti-diabetes Drugs Market 2019 Significant Growth Rate by Industry Size, Share, Market Dynamics, Development Status of Key Players Forecast to 2024


The “Combination Anti-diabetes Drugs Market” research report 2019-2024 delivers comprehensive information and valuable insights about the Combination Anti-diabetes Drugs industry. The information available in the Combination Anti-diabetes Drugs market report is not only based on the facts but also on the case studies, which analysts have included to convey appropriate information to the clients in a well-versed manner. Combination Anti-diabetes Drugs market report includes valuable information to assist new entrants, as well as established players, to understand the prevailing trends in the market.

Some Companies Are Covered in the Combination Anti-diabetes Drugs Market:

  • Novo Nordisk
  • Merck
  • Sanofi

    Get a Sample Copy of the Report –

    Market Overview:

  • The diabetes population in the world is increasing continuously. This trend is mainly due to the changing lifestyle of the majority of the population. Most of the population have unhealthy lifestyles. The change in lifestyle is due to the economic and industrial development in recent times in most of the countries. For most of the population, sedentary lifestyles and seemingly endless fast-food options have replaced the traditional ways of work, travel, and cuisine, making way for the increase of diseases, such as diabetic. WHO projects that diabetes will be the seventh leading cause of death in 2030. In 2014, 8.5% of adults aged 18 years and older had diabetes. In 2015, diabetes was the direct cause of 1.6 million deaths and in 2012, high blood glucose was the cause of another 2.2 million deaths. It expected that this number would keep increasing shortly.

    Scope of the Report:

  • The market is segmented by category (oral combinations and insulin combinations), by segment (Janumet, Ryzodeg, Xultophy, and NovoMix), and Geography

    Reasons for Buying Combination Anti-diabetes Drugs Market Report:

    • This report provides pin-point analysis for changing competitive dynamics
    • It provides a forward looking perspective on different factors driving or restraining market growth
    • It provides a five-year forecast assessed on the basis of how the market is predicted to grow
    • It helps in understanding the key product segments and their future
    • It provides pin point analysis of changing competition dynamics and keeps you ahead of competitors
    • It helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments

    For More Information or Query or Customization Before Buying, Visit at –

    Key Market Trends:

    Diabetes Patients Need More than One Drug to Control their Glycemic Level

    – Diabetes is considered to be a rich man disease, not only because of the cost of the drugs but also because of the number of medicines one must consume. Over the years, a large number of drug manufacturers has introduced combination drugs, thus making it more convenient for consumers.
    – These combination drugs have two or more active pharmaceutical ingredients, thus serving the purpose of two anti-diabetic drugs. The manufacturers have in the past started with essential oral medicines, such as Janumet and now have developed advanced insulin combinations, such as Ryzodeg and Xultophy.
    – Consumer preference for these drugs has increased considerably over time. The combination drugs market was valued 4.01 billion in 2018 and is expected to witness a CAGR of 10%, during the forecast period.

    Ryzodeg is Expected to Record a CAGR of 23%

    – Ryzodeg is a combination of ultra-long-acting insulin degludec (basal) and rapid-acting prandial insulin aspart (bolus).
    – At present, consumers need to use both the basal and bolus insulin to manage their glucose levels, but Ryzodeg acts as a perfect substitute to bolus and basal insulin.
    – Ryzodeg serves the purpose of the two insulin’s, making it more convenient for consumers. Due to its unique combination, the market for the drug is expected to grow exponentially shortly.
    – Ryzodeg is available in close to 18 countries, but Novo Nordisk plans to increase its marketing and sales resources to improve the availability of the drug inadvertently.

    Combination Anti-diabetes Drugs Market Report Provides Comprehensive Analysis of:

    • Functional market industry outline
    • Up and downstream industry examination
    • Channels and propositions believability
    • Market challenge by key players
    • Enhancement suggestions examination

    Purchase this Report (Price 5000 USD for single user license) –

    Report Highlights:

    • Market Dynamics – Drivers, Restraints, and Opportunities
    • Market Segmentation – Types, Applications, Regions, and Technology
    • Market Trends
    • Competitive Landscape
    • SWOT Analysis and Porter’s Five Forces Analysis

    Detailed TOC of Combination Anti-diabetes Drugs Market Report 2019-2024:

    1.1 Study Deliverables
    1.2 Study Assumptions
    1.3 Scope of the Study



    4.1 Market Overview
    4.2 Drivers
    4.3 Restraints
    4.4 Porter’s Five Forces Analysis
    4.4.1 Bargaining Power of Suppliers
    4.4.2 Bargaining Power of Consumers
    4.4.3 Threat of New Entrants
    4.4.4 Threat of Substitute Products and Services
    4.4.5 Intensity of Competitive Rivalry

    5.1 BY Drug
    5.1.1 Combination Drugs Insulin Combinations NovoMix (Biphasic Insulin Aspart) Ryzodeg (Insulin Degludec and Insulin Aspart) Xultophy (Insulin Degludec and Liraglutide) Oral Combination Janumet (Sitagliptin and Metformin HCl)
    5.2 Geography
    5.2.1 North America United States (Value and Volume 2012-2024) Canada (Value and Volume 2012-2024) Rest of North America (Value and Volume 2012-2024)
    5.2.2 Europe France (Value and Volume 2012-2024) Germany (Value and Volume 2012-2024) Italy (Value and Volume 2012-2024) Spain (Value and Volume 2012-2024) United Kingdom (Value and Volume 2012-2024) Russia (Value and Volume 2012-2024) Rest of Europe (Value and Volume 2012-2024)
    5.2.3 Latin America Mexico (Value and Volume 2012-2024) Brazil (Value and Volume 2012-2024) Rest of Latin America (Value and Volume 2012-2024)
    5.2.4 Asia – Pacific Australia (Value and Volume 2012 – 2024) China (Value and Volume 2012-2024) India (Value and Volume 2012-2024) Indonesia (Value and Volume 2012-2024) Japan (Value and Volume 2012-2024) Malaysia (Value and Volume 2012-2024) Philippines (Value and Volume 2012-2024) South Korea (Value and Volume 2012-2024) Thailand (Value and Volume 2012-2024) Vietnam (Value and Volume 2012-2024) Rest of Asia – Pacific (Value and Volume 2012-2024)
    5.2.5 Middle East & Africa Saudi Arabia (Value and Volume 2012-2024) Iran (Value and Volume 2012-2024) Egypt (Value and Volume 2012-2024) Oman (Value and Volume 2012-2024) South Africa (Value and Volume 2012-2024) Rest of Middle East & Africa (Value and Volume 2012-2024)

    6.1 Type-1 Diabetes population (2012-2024)
    6.2 Type-2 Diabetes population (2012-2024)

    7.1 Company Profiles
    7.1.1 Novo Nordisk
    7.1.2 Merck
    7.1.3 Sanofi



    Contact Us:

    Name: Ajay More

    Phone: US +14242530807/ UK +44 20 3239 8187

    Email: [email protected]

    Our Other Reports:

    Global Specialty Medical Chairs Market 2019: Industry Size & Share, Business Strategies, Growth Analysis, Regional Demand, Revenue, Key Manufacturers and 2024 Forecast Research Report

    Fuel-oil Outboard Engine Market 2019 – Business Size, Share, Opportunities, Future Trends, Top Key Players, Market Share and Global Analysis by Forecast to 2024

    Global Precision Tubes Market Share, Growth, Trend Analysis and Forecast from 2019-2025; Consumption Capacity by Volume and Production Value

    Metagenomics Kits Market Analysis 2019 to 2025: Report Includes Threat of New Entrants, Demand & Supply, Investment Opportunities and Forecast

  • Be First to Comment

    Leave a Reply

    Your email address will not be published. Required fields are marked *